about
Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosisEuropean Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease).Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease.Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis.Congenital adrenal hyperplasia: focus on the molecular basis of 21-hydroxylase deficiency.Valvular lesions in patients with systemic lupus erythematosus and antiphospholipid syndrome: an old disease but a persistent challenge.Natriuretic peptides in aortic stenosis.SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory.Is it time for sex-specific recommendations in aortic stenosis?[Comment on ‘‘expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States’’ Moynihan RN, Cooke GP, Doust JA, et al. PLoS Medicine; 10(8): e1001500].CYP21A2 mutations in Portuguese patients with congenital adrenal hyperplasia: Identification of two novel mutations and characterization of four different partial gene conversionsReply[General cognitive functioning and psycholinguistic abilities in children with Smith-Magenis Syndrome]European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)The Lipid Hypothesis in Calcific Aortic Valve Disease: The Role of the Multi-Ethnic Study of Atherosclerosis
P50
Q24595023-399D9A2E-51FA-489D-A5C4-38E50E07E752Q33550673-40B41F21-8D8B-4709-BFEE-535CC182EE26Q35686707-03A7824D-ED5F-47B6-8601-02FB1BC8017FQ36021472-4481A11D-776A-4E53-AE04-00F18E242E58Q36804811-BD4820D6-8206-46C6-A0B3-3B5E835DE1DDQ37990134-0B1C0935-B6FF-4838-8A01-FB7D82BCF59BQ38043634-838CAC89-AD9D-4BA6-BB83-09B8B9DF4A1BQ38387001-8C3BFDFD-4EE5-4282-AA2E-DDC43809F386Q48294881-826E007A-3BC4-48B0-9EA3-2883C4876BA6Q54320671-E8033A81-F985-40BB-86A4-F6FC3CAE47D3Q59286509-5BB3CCE7-A315-4883-9451-B46FD4396C17Q60690223-E4723B44-A82A-4EF4-B83B-F1FA66C3C0D9Q82311705-C19F3BD4-9C55-4578-8EB0-4F42BC52572EQ84143572-0328FA45-F0D0-4BE7-BA59-081DD7C0155CQ89312046-9D3FC330-D6AF-401D-A104-A4CE6456D295
P50
description
researcher ORCID ID = 0000-0003-4258-8650
@en
wetenschapper
@nl
name
Luís Francisco Moura
@ast
Luís Francisco Moura
@en
Luís Francisco Moura
@es
Luís Francisco Moura
@nl
type
label
Luís Francisco Moura
@ast
Luís Francisco Moura
@en
Luís Francisco Moura
@es
Luís Francisco Moura
@nl
prefLabel
Luís Francisco Moura
@ast
Luís Francisco Moura
@en
Luís Francisco Moura
@es
Luís Francisco Moura
@nl
P1153
16043167800
P21
P31
P496
0000-0003-4258-8650